Antibiotics Should Be One Step On FDA’s “Critical Path,” Lilly VP Cassell Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The therapeutic category is ideal for FDA’s drug development initiative because antibiotics do not pose antitrust concerns and NIH has allocated $1.7 bil. for research in the area of anti-infectives, the Lilly exec asserts.
You may also be interested in...
FDA Science Board Will Look At “Future Plans” For “Critical Path” At Nov. 5 Meeting
The meeting is one of several by the agency to discuss the drug development initiative. The final report of FDA’s good manufacturing practices initiative will also be reviewed.
FDA Science Board Will Look At “Future Plans” For “Critical Path” At Nov. 5 Meeting
The meeting is one of several by the agency to discuss the drug development initiative. The final report of FDA’s good manufacturing practices initiative will also be reviewed.
Antimicrobial Drug Development Could Benefit From Smaller Clinical Trials, FDA Says
Studies of drugs for resistant pathogens could apply data from susceptible pathogens, CDER’s Powers tells Antimicrobial Resistance Interagency Task Force meeting. The agency plans to issue several antimicrobial-related guidances this summer.